22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Specific miRNA expression profile in the blood serum of cardiac myxoma patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The profile of differentially expressed microRNAs (miRNAs) in the serum of patients with cardiac myxoma (CM) (n=30) and healthy people (n=30) was studied using miRNA microarray analysis. The expression of the candidate miRNAs was validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in the serum of 30 CM patients and 30 healthy control individuals. TargetScan, PicTar and miRanda were used to predict the possible target gene of miR-320a. The Gene Ontology database and Kyoto Encyclopedia of Genes and Genomes database were used to enrich the functions and signaling pathways of the target genes, respectively. The results showed that 4 differentially expressed miRNAs were identified, the expression levels of miR-320a and miR-1249-5p were upregulated, and those of miR-634 and miR-6870-3p were downregulated in CM patients (P<0.05). The expression levels of miR-320a and miR-634 selected for verification by RT-qPCR were in high concordance with the results of microarray analysis. Through bioinformatics, we identified 487 target genes predicted from miR-320a, that were mostly enriched in the bone morphogenetic protein signaling pathway, nicotinamide adenine dinucleotide pathway and de novo ceramide biosynthetic pathway. In our study, we reported for the first time the circulating miRNA profile of CM patients and suggested that miR-320a may participate in CM development through the ceramide signaling pathway.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Cardiac myxomas.

          K Reynen (1995)
          Although cardiac myxomas are histologically benign, they may be lethal because of their strategic position. They can mimic not only every cardiac disease but also infective, immunologic, and malignant processes. Myxomas must therefore be included in the differential diagnosis of valvular heart disease, cardiac insufficiency, cardiomegaly, bacterial endocarditis, disturbances of ventricular and supraventricular rhythm, syncope, and systemic or pulmonary embolism. The symptoms depend on the size, mobility, and location of the tumor. Echocardiography, including the transesophageal approach, is the most important means of diagnosis; CT and MRI may also be helpful. Coronary arteriography in patients over 40 years of age is generally required to rule out concomitant coronary artery disease. Surgical removal of the tumor should be performed as soon as possible; the long-term prognosis is excellent, and recurrences are rare. In follow-up examinations as well, echocardiography is essential.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ceramide-orchestrated signalling in cancer cells.

            One crucial barrier to progress in the treatment of cancer has been the inability to control the balance between cell proliferation and apoptosis: enter ceramide. Discoveries over the past 15 years have elevated this sphingolipid to the lofty position of a regulator of cell fate. Ceramide, it turns out, is a powerful tumour suppressor, potentiating signalling events that drive apoptosis, autophagic responses and cell cycle arrest. However, defects in ceramide generation and metabolism in cancer cells contribute to tumour cell survival and resistance to chemotherapy. This Review focuses on ceramide signalling and the targeting of specific metabolic junctures to amplify the tumour suppressive activities of ceramide. The potential of ceramide-based therapeutics in the treatment of cancer is also discussed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cardiac tumours: diagnosis and management.

              Primary cardiac tumours are rare, with an autopsy incidence ranging from 0.001% to 0.030%. Three-quarters of these tumours are benign and nearly half of the benign tumours are myxomas. Metastases to the heart are far more common than primary cardiac tumours. Primary cardiac tumours present with one or more of the symptoms of the classic triad of: cardiac symptoms and signs resulting from intracardiac obstruction; signs of systemic embolisation; and systemic or constitutional symptoms. They are diagnosed by use of transthoracic and transoesophageal echocardiograms, MRI, and CT scan. Whereas surgery is indicated in patients with benign tumours, systemic chemotherapy is indicated in those who have widespread or unresectable malignant disease, and chemotherapy and radiotherapy are usually combined in treatment of patients with primary cardiac lymphomas. The prognosis after surgery is usually excellent in the case of benign tumours but is unfortunately still limited in localised malignant diseases. Patients with sarcomas live for a mean of 3 months to 1 year, and those with lymphomas live up to 5 years if treated, but usually die within 1 month if untreated.
                Bookmark

                Author and article information

                Journal
                Oncol Lett
                Oncol Lett
                OL
                Oncology Letters
                D.A. Spandidos
                1792-1074
                1792-1082
                October 2018
                25 July 2018
                25 July 2018
                : 16
                : 4
                : 4235-4242
                Affiliations
                Department of Cardiac Surgery, Union Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
                Author notes
                Correspondence to: Professor Liangwan Chen, Department of Cardial Surgery, Union Hospital of Fujian Medical University, 29 Xin Quan Road, Fuzhou, Fujian 350001, P.R. China, E-mail: chenliangwan1@ 123456sina.com
                Article
                OL-0-0-9209
                10.3892/ol.2018.9209
                6144211
                30675296
                ff49a190-6c84-4a8f-8125-18203c87d387
                Copyright: © Yan et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                : 27 October 2017
                : 22 May 2018
                Categories
                Articles

                Oncology & Radiotherapy
                cardiac myxoma,microrna,aligent mirna expression profiles chip,qpcr,mir-320a

                Comments

                Comment on this article